Skip to main content

Maze Therapeutics, Inc. MAZE

Materials · Biological Products, (No Diagnostic Substances)

Full Financial Analysis →Financials Workspace →

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Key metrics (SEC EDGAR, trailing twelve months)

Revenue TTM
$167.5M
Net income TTM
$-131120000
EPS TTM
-3.05
Free cash flow TTM
$-112734000
Gross margin
-
Operating margin
-85.3%
Net margin
-78.3%
ROE
-28.9%
ROIC
-22.9%

The full deep-dive (DCF valuation, health scores, statements) lives in the Financials workspace.

Related Materials:LINAPDSHWFCXNUEDOW

Disclaimer: For educational and informational purposes only. Not financial advice. Fundamentals from SEC EDGAR. Always do your own research before investing.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.

MAZE Stock Analysis | Maze Therapeutics, Inc. | TrendNalysis